Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 2/20 | 0.81 |
| ▸ | AMDHD2 | Q9Y303 | 1/20 | 0.64 |
| ▸ | IGF2R | P11717 | 4/20 | 0.55 |
| ▸ | UMPS | P11172 | 4/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.43 |
| ▸ | ATIC | P31939 | 1/20 | 0.43 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30471819 | 1.00 | FBP1 (0.81) | FBP1AMDHD2IGF2RUMPSP2RY14 | |
| SCHEMBL708955 | 1.00 | FBP1 (0.81) | FBP1AMDHD2IGF2RUMPSP2RY14 | |
| SCHEMBL5001024 | 1.00 | FBP1 (0.81) | FBP1AMDHD2IGF2RUMPSP2RY14 | |
| SCHEMBL16710620 | 1.00 | FBP1 (0.81) | FBP1AMDHD2IGF2RUMPSP2RY14 | |
| SCHEMBL4997000 | 1.00 | FBP1 (0.81) | FBP1AMDHD2IGF2RUMPSP2RY14 | |
| SCHEMBL24450790 | 1.00 | FBP1 (0.81) | FBP1AMDHD2IGF2RUMPSP2RY14 | |
| SCHEMBL4308485 | 1.00 | FBP1 (0.81) | FBP1AMDHD2IGF2RUMPSP2RY14 | |
| SCHEMBL14016411 | 0.98 | FBP1 (0.78) | FBP1AMDHD2IGF2RUMPSP2RY14 | |
| SCHEMBL21926734 | 0.98 | FBP1 (0.78) | FBP1AMDHD2IGF2RUMPSP2RY14 | |
| SCHEMBL22107998 | 0.98 | FBP1 (0.78) | FBP1AMDHD2IGF2RUMPSP2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075713-A | Deaminase and use of transaminase in the treatment of polyglutamine diseases | — | 2026-05-26 | — | — | CN | claimed |
| EP-3874056-B1 | ENZYMATIC METHOD FOR PREPARATION OF UDP-GLCNAC | MAX PLANCK GESELLSCHAFT (DE) | 2023-06-14 | — | — | EP | claimed |
| EP-2235201-B1 | METHODS AND COMPOSITIONS FOR ASSAYING HOMOCYSTEINE | GEN ATOMICS (US) | 2012-10-31 | — | — | EP | claimed |
| EP-4747382-A1 | COMPOSITIONS AND METHODS FOR MANAGEMENT OF WHITEFLY | Natural Resources Institute (GB) | 2026-05-27 | — | — | EP | disclosed |
| CN-122075713-A | Deaminase and use of transaminase in the treatment of polyglutamine diseases | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2025019548-A9 | COMPOSITIONS AND METHODS FOR MANAGEMENT OF WHITEFLY | NATIONAL RESOURCES INSTITUTE (GB) | 2025-04-17 | — | — | WO | disclosed |
| US-20250027105-A1 | COMPOSITIONS AND METHODS FOR MANAGEMENT OF WHITEFLY | NATIONAL AGRICULTURAL RESEARCH ORGANIZATION (UG) | 2025-01-23 | — | — | US | disclosed |
| WO-2025019548-A1 | COMPOSITIONS AND METHODS FOR MANAGEMENT OF WHITEFLY | NATIONAL RESOURCES INSTITUTE (GB) | 2025-01-23 | — | — | WO | disclosed |
| US-20240350027-A1 | Methods and Apparatus for Benchtop Metabolite Profiling in Situ | VIBO HEALTH INC (US) | 2024-10-24 | — | — | US | disclosed |
| US-20230414571-A1 | APPLICATION OF SMALL-MOLECULE COMPOUND IN PREPARATION OF ANTITUMOR DRUG | SOOCHOW UNIVERSITY (CN) | 2023-12-28 | — | — | US | disclosed |
| US-11834690-B2 | Microorganisms and methods for the biosynthesis of adipate, hexamethylenediamine and 6-aminocaproic acid | GENOMATICA, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| EP-2061899-B1 | BIOMARKERS FOR PROSTATE CANCER AND METHODS USING THE SAME | METABOLON INC (US) | 2012-08-29 | — | — | EP | disclosed |
| US-20120185226-A1 | MAMMALIAN CELL LINE MODELS AND RELATED METHODS | GENOMATICA, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2401696-A1 | MAMMALIAN CELL LINE MODELS AND RELATED METHODS | GT Life Sciences, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20100292331-A1 | Biomarkers for Prostate Cancer and Methods Using the Same | METABALON, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100291605-A1 | ASSAYS FOR S-ADENOSYLMETHIONINE-DEPENDENT METHYLTRANSFERASES | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2010-11-18 | — | — | US | disclosed |
| WO-2010098865-A1 | MAMMALIAN CELL LINE MODELS AND RELATED METHODS | GT LIFE SCIENCES, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20090259451-A1 | REVERSE ENGINEERING GENOME-SCALE METABOLIC NETWORK RECONSTRUCTIONS FOR ORGANISMS WITH INCOMPLETE GENOME ANNOTATION AND DEVELOPING CONSTRAINTS USING PROTON FLUX STATES AND NUMERICALLY-DETERMINED SUB-SYSTEMS | UNIVERSITY OF DELAWARE (US) | 2009-10-15 | — | — | US | disclosed |
| US-20070298998-A1 | Biomarkers for amyotrophic lateral sclerosis and methods using the same | METABOLON, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| WO-2007087541-A2 | ASSAYS FOR S-ADENOSYLMETHIONINE-DEPENDENT METHYLTRANSFERASES | WASHINGTON STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230414571-A1 | APPLICATION OF SMALL-MOLECULE COMPOUND IN PREPARATION OF ANTITUMOR DRUG | ABCG2, SLC43A1, SLC7A5 | FBP1 2516/4885AMDHD2 1697/4885IGF2R 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.